Peter M Kash - Net Worth and Insider Trading
Peter M Kash Net Worth
The estimated net worth of Peter M Kash is at least $3 Million dollars as of 2024-11-10. Peter M Kash is the Director of Keryx Biopharmaceuticals Inc and owns about 760,750 shares of Keryx Biopharmaceuticals Inc (KERX) stock worth over $3 Million. Details can be seen in Peter M Kash's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Peter M Kash has not made any transactions after 2004-01-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Peter M Kash
Peter M Kash Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Peter M Kash owns 3 companies in total, including Capricor Therapeutics Inc (CAPR) , Arno Therapeutics Inc (ARNI) , and Keryx Biopharmaceuticals Inc (KERX) .
Click here to see the complete history of Peter M Kash’s form 4 insider trades.
Insider Ownership Summary of Peter M Kash
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CAPR | Capricor Therapeutics Inc | 2009-07-07 | director |
| ARNI | Arno Therapeutics Inc | 2008-06-03 | director |
| KERX | Keryx Biopharmaceuticals Inc | 2004-01-29 | director |
Peter M Kash Latest Holdings Summary
Peter M Kash currently owns a total of 1 stock. Peter M Kash owns 760,750 shares of Keryx Biopharmaceuticals Inc (KERX) as of January 29, 2004, with a value of $3 Million.
Latest Holdings of Peter M Kash
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KERX | Keryx Biopharmaceuticals Inc | 2004-01-29 | 760,750 | 3.36 | 2,556,120 |
Holding Weightings of Peter M Kash
Peter M Kash Form 4 Trading Tracker
According to the SEC Form 4 filings, Peter M Kash has made a total of 0 transactions in Keryx Biopharmaceuticals Inc (KERX) over the past 5 years. The most-recent trade in Keryx Biopharmaceuticals Inc is the sale of 120,000 shares on January 29, 2004, which brought Peter M Kash around $12,000.
Insider Trading History of Peter M Kash
- 1
Peter M Kash Trading Performance
Peter M Kash Ownership Network
Ownership Network List of Peter M Kash
Ownership Network Relation of Peter M Kash
Peter M Kash Owned Company Details
What does Capricor Therapeutics Inc do?
Who are the key executives at Capricor Therapeutics Inc?
Peter M Kash is the director of Capricor Therapeutics Inc. Other key executives at Capricor Therapeutics Inc include CHIEF BUSINESS OFFICER Xavier Avat , director & CHIEF EXECUTIVE OFFICER Linda Marban , and EVP & GENERAL COUNSEL Karen Krasney .
Capricor Therapeutics Inc (CAPR) Insider Trades Summary
Over the past 18 months, Peter M Kash made no insider transaction in Capricor Therapeutics Inc (CAPR). Other recent insider transactions involving Capricor Therapeutics Inc (CAPR) include a net purchase of 7,993 shares made by David B Musket , a net purchase of 2,798,507 shares made by , and a net purchase of 10,000 shares made by Collier Earl M Jr .
In summary, during the past 3 months, insiders sold 0 shares of Capricor Therapeutics Inc (CAPR) in total and bought 2,798,507 shares, with a net purchase of 2,798,507 shares. During the past 18 months, 0 shares of Capricor Therapeutics Inc (CAPR) were sold and 2,821,500 shares were bought by its insiders, resulting in a net purchase of 2,821,500 shares.
Capricor Therapeutics Inc (CAPR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Capricor Therapeutics Inc Insider Transactions
Peter M Kash Mailing Address
Above is the net worth, insider trading, and ownership report for Peter M Kash. You might contact Peter M Kash via mailing address: 787 Seventh Avenue, New York Ny 10019.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
